This manual provides instructions for using the GenScript cPass kit to detect neutralizing antibodies against SARS-CoV-2 in serum and plasma via a blocking…
The GenScript cPass™ SARS-CoV-2 Neutralization Antibody Detection Kit is an in vitro diagnostic tool designed to detect all types of neutralizing antibodies against SARS-CoV-2 in human serum and plasma. It operates as a species- and isotype-independent blocking ELISA, utilizing purified receptor binding domain (RBD) protein and the host cell receptor ACE2 to mimic virus-host interaction.
The kit includes components such as a capture plate pre-coated with hACE2, HRP-conjugated RBD, positive and negative controls, and various buffers. The assay measures absorbance at 450 nm in a microtiter plate reader, where the sample absorbance is inversely dependent on the titer of anti-SARS-CoV-2 neutralizing antibodies.
| Intended Use | detect all types of neutralizing antibodies against SARS-CoV-2 in serum and plasma |
|---|---|
| Packaging Sizes | 96 Tests/Kit, 480 Tests/Kit |
| Storage Condition (Unopened) | 2 to 8° C |
| Storage Stability (Unopened) | at least 6 months |
| Storage Stability (Opened) | up to 1 month |
| Reading Wavelength | 450 nm |
No, the kit should not be used to diagnose acute SARS-CoV-2 infection.
It is a blocking ELISA that mimics virus-host interaction using purified RBD protein and ACE2 receptor.
A single or dual wavelength microplate reader with a 450 nm filter.